Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review

Biological Psychiatry

Volumn 63, Issue 8, 2008, Pages 801-808

  Potvin, Stéphane ^a   Stip, Emmanuel ^a   Sepehry, Amir A ^a   Gendron, Alain ^b   Bah, Ramatoulaye ^a   Kouassi, Edouard ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Autoimmunity; inflammatory cytokines; meta analysis; schizophrenia

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; LEUKOCYTE; PRIORITY JOURNAL; QUANTITATIVE STUDY; SCHIZOPHRENIA; STRESS; SYSTEMATIC REVIEW; TH1 CELL; TH2 CELL; WEIGHT GAIN;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; REFERENCE VALUES; SCHIZOPHRENIA; TH1 CELLS; TH2 CELLS;

EID: 40949107708     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.09.024     Document Type: Article

References (102)

1. Brown A.S., and Susser E.S. In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 8 (2002) 51-57
2. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., et al. Association of schizophrenia and autoimmune diseases: Linkage of Danish national registers. Am J Psychiatry 163 (2006) 521-528
3. Steinke J.W., and Borish L. Cytokines and chemokines. J Allergy Clin Immunol 117 (2006) S441-S445
4. Kronfol Z., and Remick D.G. Cytokines and the brain: Implications for clinical psychiatry. Am J Psychiatry 157 (2000) 683-694
5. Raison C.L., and Miller A.H. Brain-immune system interaction: Relevance to the pathophysiology and treatment of neuropsychiatric disorders. In: Schatzberg A.F., and Nemeroff C.B. (Eds). The American Psychiatric Publishing Textbook of Psychopharmacology. 3rd ed. (2004), American Psychiatric Press, Washington DC 147-162
6. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum 52 (2005) 1960-1967
7. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136 (1986) 2348-2357
8. Dong C. Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol 6 (2006) 329-333
9. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 18 (2006) 349-356
10. McKenzie B.S., Kastelein R.A., and Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27 (2006) 17-23
11. Tato C.M., Laurence A., and O'Shea J.J. Helper T cell differentiation enters a new era: Le roi est mort; vive le roi!. J Exp Med 203 (2006) 809-812
12. Muller N., Riedel M., Gruber R., Ackenheil M., and Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci 917 (2000) 456-467
13. Muller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: An overview. Eur Arch Psychiatry Clin Neurosci 249 suppl 4 (1999) 62-68
14. Schwarz M.J., Muller N., Riedel M., and Ackenheil M. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56 (2001) 483-486
15. Schwarz M.J., Chiang S., Muller N., and Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 15 (2001) 340-370
16. Arolt V., Rothermundt M., Wandinger K.P., and Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5 (2000) 150-158
17. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., and Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38 (1995) 297-302
18. Kaminska T., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., and Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 49 (2001) 439-445
19. Ebrinc S., Top C., Oncul O., Basoglu C., Cavuslu S., and Cetin M. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. J Int Med Res 30 (2002) 314-317
20. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10 (2000) 119-124
21. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 37 (1999) 97-106
22. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuya M., Suzuki E., et al. Serum interleukin-6 in schizophrenic patients. Life Sci 49 (1991) 661-664
23. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: Potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 559-576
24. Ghezzi P., Garattini S., Mennini T., Bertini R., Delgado Hernandez R., Benigni F., et al. Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. Eur J Pharmacol 317 (1996) 369-376
25. Maes M., Meltzer H.Y., and Bosmans E. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89 (1994) 346-351
26. Hinze-Selch D., and Pollmacher T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun 15 (2001) 282-318
27. Borenstein M., and Rothstein H. Comprehensive Meta-Analysis: A Computer Program for Research Synthesis (1999), BioStat, Englewood, New Jersey
28. Johnson B.T. D-STAT. Software for Meta-Analytic Review of Research Literatures (1989), Laurence Erlbaum, Hillsdale, New Jersey
29. Cooper H., and Hedges L.V. The Handbook of Research Synthesis (1994), Russell Sage Foundation Publications, New York
30. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
31. Song F., Sheldon T.A., Sutton A.J., Abrams K.R., and Jones D.R. Methods for exploring heterogeneity in meta-analysis. Eval Health Prof 24 (2001) 126-151
32. Avgustin B., Wraber B., and Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46 (2005) 268-274
33. Baker I., Masserano J., and Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20 (1996) 199-203
34. Barak V., Barak Y., Levine J., Nisman B., and Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6 (1995) 61-69
35. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., and Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 947-957
36. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A., et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 47 (2001) 293-298
37. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., et al. Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 33-39
38. el-Mallakh R.S., Suddath R.L., and Wyatt R.J. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17 (1993) 383-391
39. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., and Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247 (1997) 228-233
40. Ganguli R., Rabin B.S., and Belle S.H. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26 (1989) 427-430
41. Ganguli R., and Rabin B.S. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Arch Gen Psychiatry 46 (1989) 292
42. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., et al. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Res 51 (1994) 1-10
43. Ganguli R., Brar J.S., Chengappa K.R., DeLeo M., Yang Z.W., Shurin G., et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52 (1995) 668-672
44. Gattaz W.F., Dalgalarrondo P., and Schroder H.C. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6 (1992) 237-241
45. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 33 (1999) 407-418
46. Katila H., Hurme M., Wahlbeck K., Appelberg B., and Rimon R. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30 (1994) 20-23
47. Kim Y.K., Lee M.S., and Suh K.Y. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 43 (1998) 701-704
48. Kim Y.K., Kim L., and Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44 (2000) 165-175
49. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1129-1134
50. Kowalski J., Blada P., Kucia K., Madej A., and Herman Z.S. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50 (2001) 169-175
51. Kowalski J., Blada P., Kucia K., Lawniczek T., Madej A., Belowski D., et al. In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia. World J Biol Psychiatry 1 (2000) 190-196
52. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr Res 32 (1998) 9-15
53. Maes M., Meltzer H.Y., Buckley P., and Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244 (1995) 325-329
54. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995) 141-152
55. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., and Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26 (1997) 221-225
56. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54 (2002) 281-291
57. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs. Schizophr Res 21 (1996) 39-50
58. Mahendran R., and Chan Y.H. Interleukin-2 levels in chronic schizophrenia patients. Ann Acad Med Singapore 33 (2004) 320-323
59. Monteleone P., Fabrazzo M., Tortorella A., and Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment. Psychiatry Res 71 (1997) 11-17
60. Mullr N., Dobmeier P., Empl M., Riedel M., Schwarz M., and Ackenheil M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry 12 (1997) 294-299
61. Muller N., Empl M., Riedel M., Schwarz M., and Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247 (1997) 308-313
62. Naudin J., Mege J.L., Azorin J.M., and Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20 (1996) 269-273
63. Naudin J., Capo C., Giusano B., Mege J.L., and Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr Res 26 (1997) 27-233
64. Nimgaonkar V.L., Yang Z.W., Zhang X.R., Brar J.S., Chakravarti A., and Ganguli R. Association study of schizophrenia and the IL-2 receptor beta chain gene. Am J Med Genet 60 (1995) 448-451
65. O'Donnell M.C., Catts S.V., Ward P.B., Liebert B., Lloyd A., Wakefield D., et al. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Res 65 (1996) 171-178
66. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., and Paul S.M. Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch Gen Psychiatry 46 (1989) 291-292
67. Rapaport M.H., and Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 90 (1994) 311-315
68. Rapaport M.H., McAllister C.G., Kim Y.S., Han J.H., Pickar D., Nelson D.L., et al. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol Psychiatry 35 (1994) 767-771
69. Rothermundt M., Arolt V., Leadbeater J., Peters M., Rudolf S., and Kirchner H. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11 (2000) 3385-3388
70. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., and Kirchner H. Immunological dysfunction in schizophrenia: A systematic approach. Neuropsychobiology 37 (1998) 186-193
71. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., and Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 40 (1996) 1294-1297
72. Schattner A., Cori Y., Hahn T., and Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun 9 (1996) 661-666
73. Schwarz M.J., Riedel M., Gruber R., Muller N., and Ackenheil M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 248 (1998) 282-288
74. Sirota P., Meiman M., Herschko R., and Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 134 (2005) 151-159
75. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47 (2001) 13-25
76. van Kammen D.P., McAllister-Sistilli C.G., Kelley M.E., Gurklis J.A., and Yao J.K. Elevated interleukin-6 in schizophrenia. Psychiatry Res 87 (1999) 129-136
77. Villemain F., Chatenoud L., Guillibert E., Pelicier Y., and Bach J.F. Decreased production of interleukin-2 in schizophrenia. Ann N Y Acad Sci 496 (1987) 669-675
78. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., et al. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production. Am J Psychiatry 146 (1989) 609-616
79. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., and Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246 (1996) 279-284
80. Xu H.M., Wei J., and Hemmings G.P. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 164 (1994) 251-253
81. Yang Z.W., Chengappa K.N., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., et al. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol Med 24 (1994) 449-455
82. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., and Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology. Schizophr Res 57 (2002) 247-258
83. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., and Wu G.Y. Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia. J Psychiatr Res 36 (2002) 331-336
84. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., and Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J Clin Psychiatry 65 (2004) 940-947
85. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., and Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30 (2005) 1532-1538
86. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 15 (1995) 121-129
87. Lucey D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 (1996) 532-562
88. Eaton W.W., Hayward C., and Ram R. Schizophrenia and rheumatoid arthritis: A review. Schizophr Res 6 (1992) 181-192
89. Mors O., Mortensen P.B., and Ewald H. A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophr Res 40 (1999) 67-74
90. Oken R.J., and Schulzer M. At issue: Schizophrenia and rheumatoid arthritis: The negative association revisited. Schizophr Bull 25 (1999) 625-638
91. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., et al. The stress cascade and schizophrenia: Etiology and onset. Schizophr Bull 29 (2003) 671-692
92. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163 (2006) 1630-1633
93. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 100 (2003) 1920-1925
94. Henderson D.C. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 66 suppl 6 (2005) 11-20
95. Wirshing D.A. Schizophrenia and obesity: Impact of antipsychotic medications. J Clin Psychiatry 65 suppl 18 (2004) 13-26
96. Juge-Aubry C.E., Somm E., Giusti V., Pernin A., Chicheportiche R., Verdumo C., et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: Upregulation in obesity and inflammation. Diabetes 52 (2003) 1104-1110
97. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., and Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35 (2002) 220-225
98. Trayhurn P., and Wood I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
99. Szuster-Ciesielska A., Slotwinska M., Stachura A., Marmurowska-Michalowska H., and Kandefer-Szerszen M. Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp (Warsz) 52 (2004) 59-67
100. Pollmacher T., Hinze-Selch D., Mullington J., Fenzel T., and Holsboer F. Smoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia. Arch Gen Psychiatry 54 (1997) 89-90
101. Duan S., Xu Y., Chen W., Liu Z., Guo T., Gao J., et al. No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 366 (2004) 139-143
102. Shirts B.H., Wood J., Yolken R.H., and Nimgaonkar V.L. Association study of IL10, IL1beta, and IL1RN and schizophrenia with tag SNPs from a comprehensive database: Suggestive association with rs16944 at IL1beta. Schizophr Res 88 (2006) 235-244